Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors
1. Citadel's £305 million short bet against GSK signals skepticism. 2. GSK stock rose 8.20% recently, but still lags behind peers. 3. GSK's share price has fallen 17.53% over five years. 4. Analysts show mixed sentiments on GSK's earnings and buyback timing. 5. Increased volatility expected for GSK due to Citadel's short position.